ReviewOncogene2005
Meeting product development challenges in manufacturing clinical grade oncolytic adenoviruses.
Review in Oncogene, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Illuminating the path to oncolysis: rise of microbial phototherapy.Journal of nanobiotechnology · 2026Review
- Development of a robust cell-based potency assay for a coxsackievirus A21 oncolytic virotherapy.Heliyon · 2024Article
- Virus-inspired strategies for cancer therapy.Seminars in cancer biology · 2022Review
- Single-step rapid chromatographic purification and characterization of clinical stage oncolytic VSV-GP.Frontiers in bioengineering and biotechnology · 2022Article
- A systematic analysis on the clinical safety and efficacy of onco-virotherapy.Molecular therapy oncolytics · 2021Article
- Interference chromatography: a novel approach to optimizing chromatographic selectivity and separation performance for virus purification.BMC biotechnology · 2020Article
- Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses.Molecular therapy. Methods & clinical development · 2016Review
- Improved replication efficiency of echovirus 5 after transfection of colon cancer cells using an authentic 5' RNA genome end methodology.Investigational new drugs · 2014Article
- Biodistribution and safety assessment of bladder cancer specific recombinant oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice.Current gene therapy · 2012Article
- Downstream processing of cell culture-derived virus particles.Expert review of vaccines · 2011Review
- Myeloma xenograft destruction by a nonviral vector delivering oncolytic infectious nucleic acid.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Article
- Flow-dependent entrapment of large bioparticles in porous process media.Biotechnology and bioengineering · 2009Article
- A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.Cancer gene therapy · 2008Article
- Viruses: tools for tumor target discovery, and agents for oncolytic therapies - an introduction.Oncogene · 2005Article
- Viruses - seeking and destroying the tumor program.Oncogene · 2005Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oncolytic adenoviruses have been considered for use as anticancer therapy for decades, and numerous means of conferring tumor selectivity have been developed. As with any new therapy, the trip from the laboratory bench to the clinic has revealed a number of significant development hurdles. Viral therapies are subject to specific regulations and must meet a variety of well-defined criteria for purity, potency, stability, and product characterization prior to their use in the clinic. Published regulatory guidelines, although developed specifically for biotechnology-derived products, are applicable to the production of oncolytic adenoviruses and other cell-based products, and they should be consulted early during development. Most importantly, both the manufacturing process and the development of characterization and release assays should be science-driven, use the best available science and technology, and must consider the unique nature of the product: a living, and mutatable, virus. Potentially significant impacts on product quality and safety stem from the possibility of genetic instability related to over-engineering the viruses (as evidenced by their recombination and/or occasional reversion to wild-type virus during manufacturing). This report provides examples of some of the critical components affecting the development and production of clinical grade material and summarizes the significant progress made in recent years.
Indexed as
Identifiers
16299538What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.